Clinical Guide to Antimicrobial Peptides: From Approved Drugs to AI-Powered Discovery | Research

The takeaway

This comprehensive review covers all clinically approved AMPs, their pharmacology and mechanisms, delivery strategies, and how AI tools are accelerating discovery of next-generation antimicrobial peptides.

Bench to bedside
Review covers the full AMP pipeline from approved clinical drugs to AI-powered discovery of next-generation candidates

What the researchers found

Several AMPs are already clinically approved with defined pharmacology, and emerging peptide modifications, delivery technologies, and AI-based discovery tools are expanding the therapeutic pipeline.

Why it matters

AMPs are no longer just laboratory curiosities—they are approved drugs treating drug-resistant infections. Understanding the full clinical landscape helps researchers develop better ones faster.

How the study worked

Comprehensive narrative review covering AMP fundamentals, clinical pharmacology of approved AMPs, modification strategies, delivery systems, and computational discovery tools.

What this study cannot tell us

Broad scope limits depth on individual drugs. Rapidly evolving AI tools may quickly outdate computational sections. Not a systematic review.

How to read the evidence

Comprehensive review integrating clinical pharmacology data, modification evidence, and computational tools. Authoritative reference for the field.

When this study was published

Published in 2025.

The bigger picture

The AMP field has matured from basic science to clinical reality. This review maps the entire translational pipeline from natural peptide to approved drug, with AI accelerating the next wave.

Questions still open

Which AI-designed AMPs are closest to clinical trials?
Can AI predict AMP toxicity and resistance development?
What regulatory pathway is optimal for modified natural AMPs?

Common questions

Are antimicrobial peptides already used as medicines?

Yes, several AMPs are approved drugs used to treat infections. Examples include colistin for resistant Gram-negative bacteria and daptomycin for resistant Gram-positive infections. More are in clinical trials.

How is AI helping find new antimicrobial peptides?

AI can screen millions of potential peptide sequences, predict which ones will be antimicrobial, and even design entirely new peptides optimized for potency and safety — dramatically accelerating the discovery process.

Read the original research

Antimicrobial peptides and proteins: Mechanism of action and therapeutic potential.

Advances in protein chemistry and structural biology, 149, 143-170

View on PubMed ↗Publisher’s paper ↗

Citation

Dubey, Ateendra Kumar; Mishra, Amit; Prajapati, Vijay Kumar. (2026). Antimicrobial peptides and proteins: Mechanism of action and therapeutic potential.. Advances in protein chemistry and structural biology, 149, 143-170. https://doi.org/10.1016/bs.apcsb.2025.07.001